Strategic Acquisition Target TTP Group is facing a potential acquisition by Exyte as of Sep 2024, indicating a strategic shift in ownership. Sales opportunities exist in engaging the new parent to continue leveraging TTP’s strong positions in chemical and pharmaceutical consulting and engineering, as well as exploring cross-sell of TRIPLAN and PHARMAPLAN capabilities within Exyte’s expanded portfolio.

European Footprint Expansion With 29 locations across Austria, Belgium, France, Germany, Switzerland, and India and recent office openings in Belgium and Stein, there is a clear opportunity to target regional expansion projects, integrate local regulatory compliance services, and propose site-specific engineering and commissioning packages to multinational pharma and chemical clients.

Pharma and Chemicals Focus PHARMAPLAN and TRIPLAN together cover feasibility, EPCMV, and on-site support across pharmaceutical and chemical sectors. Sales opportunities include pursuing large-scale investment projects, modernization and optimization programs, and on-site operations support for lifecycle services in pharma manufacturing and chemical processing facilities.

Mid-market Financials Reported revenue range of $1M–$10M and a mid-sized employee base suggest a scalable engineering services model that can be positioned for tiered expansion. Propose value-based packages, modular EPCM/EP/OC services, and performance-based incentives to align with potential buyers or partners looking for flexible engagement models.

Brand Strength and Synergy Strong exposure of established brands TRIPLAN and PHARMAPLAN within the process industry creates cross-selling opportunities, especially in regions where Exyte is expanding. Focus on joint go-to-market strategies, joint collateral, and integrated project delivery to win larger, multi-disciplinary projects.